1 / 57

Update on the biology and risk-adapted CLL management in 2013 and the prospect of novel therapies

Update on the biology and risk-adapted CLL management in 2013 and the prospect of novel therapies. Sami N. Malek, MD Associate Professor Department of Internal Medicine Division of Hematology and Oncology University of Michigan Ann Arbor, Michigan smalek@med.umich.edu.

fox
Télécharger la présentation

Update on the biology and risk-adapted CLL management in 2013 and the prospect of novel therapies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on the biology and risk-adapted CLL management in 2013 and the prospect of novel therapies Sami N. Malek, MD Associate Professor Department of Internal Medicine Division of Hematology and Oncology University of Michigan Ann Arbor, Michigan smalek@med.umich.edu

  2. Disclosure InformationSami N. Malek, MD • I have the following financial relationships to disclose: • Speaker’s Bureau for Roche and Teva.

  3. CLL: Introduction • CLL is the most common leukemia in the western world. CLL is rare is Asia. • CLL incidence is about 15,000 cases with about 4,400 deaths per year in the US. • Mean age at diagnosis is 70 years. • Male to female ratio is ~2:1. • CLL can cluster in families (familial CLL). • Unaffected relatives of CLL patients demonstrate an elevated frequency of Monoclonal B-cell Lymphocytosis (MBL) Rawstron, Blood 2002and others.

  4. CLL and MBL • Essentially all CLL is preceded by MBL Landgren, NEJM 2009. • MBL is 100x more frequent than CLL. • CD5+ CLL-like MBL demonstrates clonal genomic lesions (13q14, trisomy 12) similar to CLL Lanasa, Leukemia 2011, Fazi, Blood 2011 and others. • Clinical CD5+ CLL-like MBL demonstrates progression to CLL at a frequency of 1%/year. • Low count CD5+ CLL-like MBL rarely progresses to CLL and sometimes regresses.

  5. Major biological phenomena underlying CLL pathogenesis • Quality and strength of B-cell receptor signaling including self-aggregation and antigenic CLL cell stimulation. • Non-malignant cell to CLL cell signaling. Microenvironment • Cytokine to CLL cell signaling. • Survival dependence of CLL cells on the expression of Bcl2 family members (Mcl1, Bcl2). • CLL transformation to aggressive NHL or HL (Richter’s transformation) Puente et al, Nature 2011, Rossi, Blood 2011 others.

  6. Major genomic phenomena underlying CLL pathogenesis • Recurrent acquired genomic copy number aberrations (aCNA; del17p, del11q, t12, del13q14) Dohner, NEJM 2000 and others. • Genomic complexity. • Recurrent gene mutations (TP53, Notch1, SF3B1). • miRNA deregulations Calin, PNAS 2002 and others. • Epigenetic deregulation?

  7. CLL disease progression/evolution • Aberrant HSC (cell intrinsic?)Kikushige, Cancer Cell 2011 • Pro-B expansion and antigen encounter • CLL-like MBL • Early stage CLL • Progressive CLL • Treated CLL followed by relapsed CLL • Multi drug resistant CLL • Terminal CLL

  8. Major phenomena underlying CLL clinical behavior • CLL has a highly varied clinical course. • Phase 1: Diagnosis to need of first therapy (TTFT). • Short TTFT independently associates with expression of ZAP70, IgVH-UM status, INSR expression/del11q, TP53 mutations/del17p and elevated genomic complexity. • Phase 2: Time from first therapy to death (Survival). • Short survival is determined by TP53 mutations/del17p, del11q status and most comprehensively SNP array-based elevated genomic complexity. • Most CLL markers are unstable longitudinally necessitating outcome analysis from the dates of marker measurements.

  9. Terminology • Progressive CLL: Need of therapy within a few years from diagnosis. • Aggressive CLL: Short OS. • Predictive markers: Predictive of response type after therapy (CR, PR or PD). • Prognostic markers: Predictive of OS.

  10. CLL genomics: Recurrently mutated genes • Gene mutation frequency at CLL diagnosis: • TP53 7-10% • SF3B1 6-9% • NOTCH1 4-6% • ATM 3-5%, few unbiased estimates. • POT1, BIRC3, MYD88, ZMYM3, CHD2, LRP1B, BRAF all 2-5%. • 515 kinase genes in CLL: essentially unmutated

  11. CLL genomics: Recurrently mutated genes • TP53 mutations/aberrations anatomy: • Exon 4-10, majority are missense mutations in DBD. Some are nonsense, frameshift or splice site mutations. • Del17p plus TP53 mutated (most common). • TP53 mono-allelically mutated and the retained TP53 allele wt (2%). • Copy-neutral LOH at 17p plus TP53 mutated. • Very uncommon: Del17p and TP53 wt allele.

  12. P53 exons 2-10 mutations and overall survival in CLL

  13. Del17p in CLL summary (molecular) • Del17p carries aberrant p53 (mutations or absent expression) (Gaidano 1991; El Rouby, 1993, Wattel, 1994; Dohner, 1995, Dohner, 2000; Saddler 2008, others) • Copy neutral LOH (aUPD) at 17p exists in CLL and is associated with homozygous p53 mutations and is undetectable by FISH (Saddler, 2008). • Sporadic p53 mutations in CLL exist without structural 17p abnormalities, although estimates of the true frequency need knowledge of aUPD (Zenz, 2008; Rossi, 2008 Dicker, 2009). • The frequency of p53 mutations in fludarabine-refractory CLL is higher than in untreated CLL (Zenz, 2009).

  14. Del17p in CLL summary (clinical) • Early stage CLL with del17p can be non-progressive for years and should be observed(Best, 2009; Tam, 2009). • PFS and OS of CLL patients with del17p is shortened relative to other FISH-defined CLL groups (estimated OS ~5-8 years)(Dohner, 2000; Shanfelt, 2006; Grever, 2007; Tam, 2009). • Del17p patients should be enrolled into clinical trials using p53 status-insensitive drugs/ approachesand should be considered early for allo-RIT/MUD-RIT.

  15. Approach to CLL patients with del17p/TP53 mutations • Young and medically fit: Induction followed by RIC-SCT in first remission. • Regimens: FCR, other CIT combinations, alemtuzumab, high dose methylprednisone plus rituximab, high dose methylprednisone plus alemtuzumab, induction on a clinical protocol. • Ideal patient group for targeted clinical trials with novel agent acting through non-genotoxic pathways.

  16. CLL genomics: Recurrently mutated genes • SF3B1 mutation anatomy: • Always heterozygous missense mutations affecting selected codons. • Presumed effects on 3’-mRNA splice site recognition with activation of cryptic aberrant 3’- splice sites resulting in aberrant mRNA. • Critical gene targets in CLL unknown. • Functional consequences unknown. • Quesada, Nature Genetics 2011, Wang, NEJM 2011, Rossi, Blood 2011. • Associated with modest shortening of PFS (preliminary).

  17. CLL genomics: Recurrently mutated genes • NOTCH1 mutation anatomy: • Frameshift mutations are most common, non sense and missense mutations are also found. Puente, Nature 2011, Rossi, JEM 2011 • Localized to exon 34 targeting the PEST domain. • Mutations result in NOTCH1 protein stabilization. • Mutated NOTCH1 likely remains Notch ligand- dependent for activation. • Functional consequences are largely unknown. • NOTCH1 mutations almost always occur in ZAP70+/IgVH UM CLL, often together with t12. Shedden, Leukemia 2011, Balatti, Blood 2011.

  18. CLL genomics: Recurrently mutated genes and survival • TP53: major negative effect, short OS. • ATM: Little or no effect on OS. • NOTCH1: conflicting data, additional prospective evaluations are needed, association with Richter’s transformation. • SF3B1: likely minor effects on PFS but further research is needed. • Others: unknown.

  19. Deletion 11q

  20. SNP 6.0 profiling of 11q in ~255 CLL cases

  21. 11q deletions and overall survival in CLL

  22. Del11q biology • Associated with elevated genomic complexity indicative of defects in DNA ds break response and DNA maintenance. • Associated with high insulin receptor levels. • Acquired over time indicative of a genomic driver status. • Almost all del11q are IgVH unmutated. Why?

  23. CLL del11q interim summary • The reason for relatively rapid disease progression in CLL with del11q pre therapy is not well understood. • CLL del11q is associated with shortened OS relative to other genomically defined CLL groups(Fegan, 1995; Dohner, 1997, Neilson, 1997, Dohner, 2000, Shanafelt, 2006) • Del11q exists with (~30%) and without (~70%), ATM mutations; thus, ATM defects alone are not sufficient to explain del11q biology or clinical features comprehensively(Bullrich, 1999; Schaffer, 1999; Stankovic, 1999; Austen, 2005, Austen, 2007).

  24. Management of CLL patients with del11q • Induction: FCR. Evidence from CLL8 trial and other trials suggest improvement in PFS using alkylators in 11q. Negative prognostic effect has been markedly reduced. • Remission duration <2 years, re induction followed by RIC-SCT. • Remission duration >2 years, individualized therapy for relapsed CLL.

  25. Genomic complexity in CLL

  26. Complex (aberrant) karyotypes /genomic complexity in CLL • Chromosomal translocations in CLL are associated with aggressive disease(Mayr, 2006; Van Den Neste, 2007). • Complex (aberrant) karyotypes in CLL are associated with aggressive disease(Juliusson, 1990, Fegan, 1995, Dicker, 2006, Haferlach, 2007, Dicker, 2009). • Elevated SNP array-based acquired genomic complexity in CLL is associated with aggressive disease(Kujawski, 2008; Gunnarsson, 2009, Ouillette 2011). • FISH with 2 or more findings is 90% sensitive and 50% specific for genomic complexity.

  27. CLL genomics based on SNP 6.0 array profiling • Prospective single institution (Univ. of Michigan) CLL cohort (since 2005). • FACS sorted CD19+ and CD3+ cells. • Generated SNP 6.0 array data on 255 paired specimens (255 CD19+ and 255 CD3+ DNA). • Refined software tools to analyze SNP 6.0 data: 64-bit version of dChipSNP (Cheng Li, DFCI), PLUT (pre LOH tool unification tool) and the LOHtool version 2. • Visual lesion scoring using dChipSNP heatmaps for paired copy number and LOH analysis (exclusion of CNVs).

  28. Genomic complexity in CLL based on SNP 6.0 array data • 0 subchromosomal aCNA 72/256~28% • 1 subchromosomal aCNA 83/256~32% • 2 subchromosomal aCNA 51/256~20% • ≥3 subchromosomal aCNA 50/256~20% (range 3-22)

  29. Results of multivariate analyses for overall survival risks in previously untreated patients (N=190)

  30. Results of multivariate analyses for overall survival risks in previously untreated patients (N=190)

  31. Genomic complexity in CLL conclusions • Genomic complexity is present in 20-35% of all CLL and identifies aggressive CLL (short OS). • ~50% of all genomically complex CLL cases carry p53 exon 2-10 mutations. • Work is in progress attempting to identify other genes with effects on genomic instability in CLL. • Overall, genomic complexity identifies a larger high risk group of CLL than p53 mutations/ del17p. • CLL with elevated genomic complexity is a prime target for non genotoxic therapy approaches.

  32. Indications for RIC-allo-PBSCT • Young (<65-70 years) and medically fit and • Del17p or • TP53 mutations or • Complex karyotype or even complex FISH or • Remission durations following chemoimmunotherapy (FCR, FR, BR, PCR) of <2 years.

  33. A few clinical perls • Ignore the platelet count in CLL • Do not us the ALC as a basis for a treatment decision. • AIHA in CLL can be difficult to diagnose. Suspect in any HGB drop or rise in MCV. If treating AIHA, taper steroids slowly. • FCR is not for the elderly (>65-70). • Do not shorten life by attempting a CR in patient that failed potent upfront CIT. • Define Rai stage 3 as HGB <11g/dl AND a packed marrow.

  34. A few more clinical perls • Avoid single agent rituximab. • Campath sc can be given to elderly patients with del17p and LN < 3 cm, monitor for CMV. • Chlorambucil (+ rituximab) likely is at least as good as more potent therapies in the elderly patient with co-morbidities. • There is no current indication for lenalidomide in CLL. • Use IVIG only as secondary prophylaxis and not lifelong.

  35. The new era of non-genotoxic (targeted) therapies in CLL

  36. Novel therapeutic approaches in CLL (non-genotoxic approaches) • Targeting the B-cell antigen receptor and critical cell surface receptors involved in CLL cell – micro environment interaction (Ibrutinib, GS-1101, Syk-inhibitors). • Targeting critical anti-apoptotic proteins like Bcl2, Bcl2-XL (ABT-199) and indirectly Mcl-1. • Targeting T-cells to engage CLL B-cells for cell-mediated direct cell kill (chimeric antigen receptors or CARs). • Activating wild type TP53 protein through use of MDM2 inhibitors.

  37. Novel therapeutic approaches in CLL (non-genotoxic approaches) • Selective inhibition of PI3K-delta: • GS-1101 (CAL-101). • Inhibits multiple important CLL signaling pathways (BCR and cytokine receptor and cell to cell interaction pathways). • Reduces protective effects of the micro environment on CLL cells and results in egress of CLL cells from secondary lymphoid organs.

  38. Novel therapeutic approaches in CLL (non-genotoxic approaches) • ASH 2012 abstract #191: Phase 1 Study of GS-1101 in combination with rituximab, or bendamustine, or bendamustine/rituximab. • Daily oral GS-1101 in various combinations. • Pre-treated CLL patient population with a median of 2,3 or 4 prior therapies (no therapy details provided). • Approximately 60% had LN > 5 cm at enrollment. • ≥ Grade 3 neutropenia was very common in the GS-1101 + bendamustine treatment arms (70%)

  39. Novel therapeutic approaches in CLL (non-genotoxic approaches) • ASH 2012 abstract #191: Phase 1 Study of GS-1101 in combination with rituximab, or bendamustine, or bendamustine/rituximab. • Overall response rate (ORR) 78%-87%. • Essentially all PRs. • LN size reductions median -75% • 1-year PFS was 74%-87%.

  40. Novel therapeutic approaches in CLL (non-genotoxic approaches) • Bruton’s tyrosine kinase (Btk) inhibitors (PCI-32765). • Btk is a critical mediator of BCR signaling as well as signaling through multiple other CLL cell surface receptors. • Tonic non antigen-driven BCR signaling is needed for B-lymphocyte survival. • Irreversible inhibitor, oral, once daily. • Rapid reduction in LN size concomitant with lymphocytosis (CLL mobilization).

  41. Novel therapeutic approaches in CLL (non-genotoxic approaches) • ASH 2012 abstract #189: Phase Ib/II study of Ibrutinib in treatment naïve and relapsed or refractory CLL… • TN: all >65 years • RR: all ≥ 2 (median of 4) prior treatments incl. purine analogues. • HR: relapse within 2 years from CIT or del17p.

  42. Novel therapeutic approaches in CLL (non-genotoxic approaches) • ASH 2012 abstract #189: Phase Ib/II study of Ibrutinib in treatment naïve and relapsed or refractory CLL…. • TN: ORR 71%, mostly PRs • RR: ORR 67%, mostly PRs • HR: ORR 50%, all PRs • In all arms there were additional PRs with lymphocytosis. • Response duration or PFS at 22 months f/u: • 76% for RR and HR • 94% for TN.

  43. Novel therapeutic approaches in CLL (non-genotoxic approaches) • ASH 2012 abstract #187: Study of Ibrutinib in combination with rituximab in high risk CLL patients…. • Patient population: del17p/TP53 mutated, response to CIT <36 months or relapsed CLL with del11q. • Daily Ibrutinib plus weekly R x 4, followed by daily Ibrutinib plus monthly R x 5, followed by daily Ibrutinib. • Toxicities: Mostly grade 2 or less: diarrhea, rash, fatigue, URIs, arthralgia. • Some higher grade neutropenias.

  44. Novel therapeutic approaches in CLL (non-genotoxic approaches) • Inhibitors of Syk. • Activity as single agents in NHL and CLL. • Selective and less selective inhibitors. • Synergistic with fludarabine. • Currently not in an active CLL trial but may resume after trials in RA or DLBCL are completed.

More Related